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Abstract 
A human heavy chain variable domain (VH) was expressed in bacteria for structural analysis by NMR spectroscopy. NMR analysis was initially 
impossible due to the short transverse proton relaxation time of the VH, probably caused by aggregation through the exposed interface naturally 
in contact with the light chain. The relaxation time was improved to normal values when this interface was mutated to mimic heavy chains of camel 
antibodies naturally devoid of light chains and through the use of the detergent CHAPS. Assignment of NMR signals will now be possible after 
isotopic labeling. Implications for the design of VH domains as minimum size immunoreagents are outlined. 
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Through recombinant DNA technology antibody 
genes can be manipulated at will. They have been mu- 
tated, dissected into domains, fused to other proteins and 
successfully expressed in eucaryotic cells and bacteria [ 11. 
Many attempts have been made to design minimum size, 
antigen binding immunoglobulin fragments (minimum 
recognition units), because these might, for example, im- 
prove tissue penetration when used as immunoreagents 
in pharmaceutical applications. The so called Fv frag- 
ment, formed by the variable domains of heavy (VH) and 
light chain (VL), was most commonly viewed as this unit. 
However, earlier observations indicated that some heavy 
chains could bind antigen in the absence of a light chain 
[24]. Also VH domains with high affinities were de- 
tected in expression libraries of mouse VH genes [5]. 
However, a more detailed biochemical analysis of iso- 
lated VH’s was hampered by their low expression and 
poor solubility (L.R., unpublished). More recently, 
camelid immunoglobulins devoid of light chains have 
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Abbreviations: BSA, bovine serum albumin; CDR, complementarity 
determining region; CHAPS, 3-[(cholamidopropyl)dimethylammonio]- 
I-propanesulfonate; 2D-TOCSY, two dimensional total correlation 
spectroscopy; FR, framework region; IPTG, isopropyl B-D-thiogalac- 
topyranoside; NMR, nuclear magnetic resonance; PBS, phosphate 
buffered saline; PCR, polymerase chain reaction; scFv, single chain Fv 
fragment; VH, heavy chain variable region; VI.,, light chain variable 
region. Mutants are denoted by the original amino acid, followed by 
residue number and new amino acid. 
The 0x13-VH gene was derived from the scFv clone aOx13 1123. The 
VH and its mutants were expressed m the absence of a VL using a 
pUCl9-based expression vector described previously [13]. The 0x13- 
VH was mutated to VH-PI by site-directed mutagenesis n Ml3 with 
the oligonucleotide, CAMEL2 (Fig. 1). A library of VH mutants was 
prepared in a polymerase chain reaction and cloned into the expression 
vector using the newly introduced PstI site in CDR2 (Fig. 1) and the 
polylinker Hind111 site. PCR was performed for 30 cycles at 92’C for 
1 min, 36°C for 1.5 min and 72°C for 2 min with the oligonuleotide, 
CAMEL,3 (Fig. 1) and the Ml3 reverse primer for amplification of the 
VH-PI gene. 
been described [4]. The VH domains in the camelid anti- 
bodies presumably form two antigen binding sites just 
like immunoglobulins with light chains. 
Through antibody engineering it also became possible 
to undertake detailed NMR studies on immunoglob- 
ulins. As triple resonance NMR techniques [7] should 
enable complete assignments of proteins up to 30 kDa, 
solution structures even of entire Fv fragments (usually 
12.5 kDa VH plus 11.5 kDa VL) will eventually be ob- 
tained based on nuclear Overhauser enhancement data. 
Fv’s were successfully labeled with “N and 13C [S-l 1 J, 
but, to date, poor solubility and short ‘H relaxation 
times have prevented their complete assignment. On the 
other hand, an isolated VL was completely assigned 
[lO,l 11. Little progress, however, has been made with 
respect to isolated VH’s, which would be more likely 
candidates for minimum recognition units. 
Therefore we started the analysis of a human VH with 
the aim of developing a small immunoreagent and analy- 
sing it by NMR spectroscopy. 
2. Experimental 
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2.2. Screening 
The VH library m the Escherichza coli strain, JM109. was screened 
for expression after transfer of bacterial colomes from TYE agarose 
plates containing 100 mg/l ampicillin and 1% glucose to Hybond-N 
membranes (Amersham). The colonies were grown on the membranes 
for another 6 h under identical conditions. Membranes were then 
washed on filter paper soaked in 2 x TY medium containing 100 mg/l 
ampicillin and 1 mM IPTG, placed onto several layers of nitrocellulose 
membranes (Schleicher & Schiill) and transferred to a new TYE agarose 
plate containing ampicillin and IPTG. After 24 h induction at 37°C. 
membranes were washed m PBS, blocked with 3% BSA in PBS and 
Incubated with protein A conjugated peroxidase (Sigma; 1 ,ug/ml m 3% 
BSAIPBS) for 1 h at room temperature. Membranes were finally 
washed with PBS and developed with 4-chloro-I-naphtol/HzOz. Colo- 
mes giving the darkest spots were rescued and their double stranded 
plasmid DNA was sequenced by the dideoxy method. 
2.3 Protem purification 
VH was purified from supernatants of bacterial cultures grown to 
confluency at 37°C in 2 x TY medium containing 0.1% glucose and 100 
mg/l ampicillin and after induction with 1 mM IPTG for 24 h at 30°C. 
Supernatants were passed through protein A-Sepharose (Pharmacia), 
which was then washed with 0.5 M NaCl in PBS. VH was eluted with 
10 mM phosphate buffer (pH 2.6) and immediately neutralised. 
47.4 NMR spectroscopy 
D20-NMR spectra were recorded with 1 mM VH samples in 10 mM 
phosphate, 200 mM NaCl, pH,,, 6.2 in 99.9% DzO or in the additional 
presence of 10 mM CHAPS. The H,O spectrum was recorded in the 
presence of CHAPS under identical conditions except for the use of 
90% H,O/lO% DzO instead of 99.9% D,O. D,O-TOCSY [14] (z, = 37 
ms) spectra were acquired at 3 13 K on a Bruker AMX-500 spectrometer 
using a spectral width of 12,500 Hz (2048 complex points acquisition, 
160 scans) in f2 and 240 increments for a spectral width of 4,000 Hz 
m fl. For the H20-TOCSY experiment (z, = 57 ms) 256 transients were 
acquired with 300 increments for a spectral width of 6,000 Hz in fl. 
Data were analysed with UXNMR (Bruker) software. Transverse pro- 
ton relaxation times ( T2) were estimated from the line width (at half 
peak height) of the non-exchanged amide signals in D,O spectra proc- 
essed in f2 without window functions. An average JNHCaH coupling 
constant of 8 Hz was assumed as these amides are likely to be part of 
the immunoglobulin domain B-sheet structure. 
3. Results 
3.1. The human VH3 domain 
As a first step towards the design of a minimum size, 
antigen binding immunoglobulin fragment and its struc- 
tural analysis by NMR spectroscopy, we decided to 
study the human heavy chain variable domain, Ox 13-VH 
(Fig. I), which could later also be used as a building 
block in the NMR analysis of a human antibody Fv 
fragment. The 0x13-VH was derived from the single 
chain Fv (scFv) aOx1 3 [12] and originated from the 
human VH3 family [ 151, which binds protein A [ 161. This 
enabled a simple one step purification of both VH and 
scFv with protein A-Sepharose. The 010x13 scFv was 
selected from a library of phage surface-expressed 
human scFv’s with randomised VH-CDR3 residues 
through binding to 2-phenyloxazolone [12]. The 0x13- 
VH on its own has no known specificity. 
The 0x13-VH was expressed well even when not part 
of a scFv. About 6 mg of VH could be purified from 1 
1 of bacterial culture. In contrast VH domains of other 
antibody Fv fragments studied in our laboratory were 
expressed at very low levels (about 0.1 mg/l; L.R., un- 
published). However NMR analysis of the VH (13.5 
kDa) seemed impossible due to its large line width. Even 
at 3 13 K the transverse proton relaxation time, T,, was 
estimated as only 14.5 ms for its DzO stable amides 
compared to 23 ms measured for the orOxl3 scFv (J.D. 
and L.R., in preparation). The Tz value is a good indica- 
tor of the success of multi-dimensional NMR experi- 
ments with larger proteins, where cross-peak heights 
scale proportionally to the inverse correlation time and 
thus the proton T, [17]. Consequently for the 0x13-VH 
very few cross-peaks were observed in 2D-TOCSY spec- 
tra (Fig. 2). 
3.2. ‘Camelising’ the human VH3 
As the broad lines of the 0x13-VH were probably due 
to aggregation caused by the exposed VHNL interface, 
we mutated this interface through protein engineering. 
The modifications were based on sequences published 
for two VH genes found in camelid immunoglobulins 
devoid of light chains [6]. The sequence of their FR’s and 
that of the human VH3 family were remarkably similar 
except for three residues (44, 45 and 47) in FR2 (Fig. l), 
usually highly conserved in VH domains. These residues 
(G44, L45 and W47 in the human VH3) are located in 
the VHNL interface and the side chains of residues 45 
and 47 point towards the VL in known antibody struc- 
tures [ 181. 
Initially the mutant VH-Pl was engineered to match 
the camel VH most hydrophilic with respect to these 
three residues (VH-G44E, L45R, W47G). At the same 
time a restriction site close to these residues (causing a 
conservative IleNa mutation of residue 51 in CDR2, 
Fig. 1) was introduced to simplify further mutations in 
this region through the use of PCR. As the two published 
camel VH’s differed at position VH-47 (glycine or phen- 
ylalanine) we also prepared a library of VH’s ran- 
domised at position 47 containing 0x13-VH mutants of 
the type: G44E, L45R. W47X, 151V (Fig. 1). 
As the engineered VH domains were to be analysed by 
NMR spectroscopy, highly expressed mutants seemed 
initially of greatest interest. Therefore the library of VH 
mutants was screened for expression in a blot assay of 
bacterial colonies using protein A-conjugated peroxi- 
dase. Sequences of the strongest-expressing clones indi- 
cated that a branched, aliphatic side chain of residue 
VH-47 was critical for good expression. Among nine 
sequenced clones three leucine, isoleucine and valine res- 
idues each were found at position VH-47. The originally 
designed mutant, VH-PI, gave only a weak signal in the 
screening experiments, whereas the wild-type 0x13-VH 
was clearly better expressed than even the best expressers 
of the library. 
Two mutants were purified and analysed by NMR: the 
highly expressed VH-P8 (0x13-VH-G44E,L45R,W471, 
151V) and the moderately expressed VH-PI (0x13-VH- 
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a) Partial DNA sequence of the 0x13-VXi 
.&ax 
Mutants . . . P G K E R ED/XV S A V S G 
CAMEL3 3'- CTC TCC CTC NNS CAG m CGT CAA TCA CCA - 5' 
CAMEL2 3'- CC TTC CTC TCC CTC CCC CAG UA CGT CAA TCA CCA T- 5' 
Oxl3VH 5'.. .GCT CCA GGG AAG GGG CTG GAG TGG GTC TCA GCT ATT AGT GGT AGT... 3' 
FR2 . ..A P G K G L E W V S A I S G S . . . CDR2 
40 44 45 41 50 52 52a 53 
b) VH protein sequences 
FRl 1 5 10 15 20 25 30 
Hu Oxl3VH QVQLVESGGGLVQPGGSLRLSCAASGFTFS 
HuVH-P8 ._........................_... 
HuVH-PI . . . . . . . .._..................._ 
Camel VHa . . s.. . ..*..... G I . s 
Camel VHb . S..A.........S.S I 
CDRl/FRZ 31 35 36 40 45 49 
Hu Oxl3VH SYAMS WVRQAPGKGLEWVS 
HuVH-P8 . . . . . . . . . . . ..ER. I.. 
Hu VH-Pl . . . . . ER .G 
Camel VHa :F:iG:::ER.G;i 
Camel VW .Y......ER.F.. 
CDR2 SO 52 a53 55 60 65 
HU OX13VH AISGSGGSTYYADSVKG 
HuVH-P8 .V............... 
HuVH-Pl .V............... 
Camel VHa 
Camel VHb 
FR3 66 70 75 80 82 a b ~83 85 90 94 
Hu Oxl3VH RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR 
HuVH-P8 . . . . . . . . . . t. _ . . . . . . . . . . . .._ . . . . . 
HuVH-Pl . . . . . . . . . . . . . . . . . . . . . . . .._.._... 
CamelVHa . . . ..Q.STLK.M..L..N.KP...GT....A 
CamelVHb . . . ..Q.SA...V.......KP....M...KI 
CDR3lFR4 95 100 102 103 105 110 113 
Hu Oxl3VH LKKYAFDY WGQGTLVTVSS 
HuVH-P8 . . . . ..I. ..__......I 
HuVH-Pl .._ . . . . . . . _ . _ . . . . . . 
Camel VHa f . . . . Q..... 
Camel VHb Q .*... . . . . . 
Fig. 1. VH sequences. Protein residues are numbered according Kabat et ai. [23]. Dots indicate sequence identity to the 0x13-VH. Empty spaces 
denote regions of the camel VH domains, for which no sequence was published [6]. S = C or G, X = any amino acid. 
G44E,L45R,W47G,I51V). For VH-P8, 4 mg of protein 
were purified from 1 1 of bacterial culture, whereas for 
VH-Pl it was only 1 mg. 
In the NMR experiments the line width of VH-P8 was 
still poor (Tz = 16 ms), and only few cross-peaks were 
observed in the NMR spectrum (Fig. 2). However, for 
VH-PI a dramatic increase in the relaxation time was 
observed (I; = 29 ms), which now was typical for a pro- 
tein of its size. Accordingly strong cross-peaks were ob- 
served in its 2D-TOCSY spectrum (Fig. 2). 
Through the replacement of hydrophobic with hydro- 
philic residues in the exposed VHNL interface of the 
0x13-VH its relaxation time was increased from 14 ms 
to 29 ms. Unfortunately these mutations decreased the 
expression, considerably hampering for economic rea- 
sons future NMR analyses, which depend on isotopic 
labeling. For this reason we explored a different way to 
decrease the line width of the VH. 
3.3. Adding detergent 
Recently the detergent CHAPS was successfully used 
to improve the T2 of the 19 kDa protein, calcineurin B 
[19]. The presence of even non-deuterated detergent 
would ultimately not interfere with the NMR analysis so 
long as heteronuclear techniques were applied using iso- 
topically enriched protein. 
10 mM CHAPS was added to the D,O samples of the 
three VW domains. The T2 of the wild-type 0x13-VH 
increased from 14.5 ms to 20 ms and the T2 of the VH-P8 
mutant from 16 ms to 29 ms. The latter matched the 
value measured for the VH-Pl mutant in the absence of 
CHAPS. Now strong cross-peaks were observed for the 
0x13-VH and VH-P8 in 2D-NMR spectra similar to 
those seen with the VH-Pl mutant (Fig. 2). In contrast 
addition of CHAPS to VH-PI improved neither its line 
width nor the TOCSY spectra (Fig. 2). 
The effect of the detergent seemed to be highly specific. 
288 
a21 
a-, -, -,-,-L-,-,--/-,-,-i / -/ _ (,_/_, _,_,~ - -/-i -/-, -,--,-, -+--/--, 
7.5 7.0 6.S 7.5 7.0 6.5 
f2, PPm 
Fig. 2. Aromatic region of TOCSY ZD-spectra recorded in D,O with: (al) 0x13-VH; (a2) 0x13-W in the presence of 10 mM CHAPS; (bl) VH-PS; 
(b2) VH-PS in the presence of 10 mM CHAPS; (cl) VH-Pl; (~2) VH-PI in the presence of 10 mM CHAPS. 
Adding CHAPS, for example, did not improve the line 
width of the intact scFv aOx13 (J.D. and L.R., in prep- 
aration), in which the VHNL interface was obviously 
not exposed to the solvent. In the case of the VH do- 
mains, CHAPS improved the T, of the two VH’s with 
very broad lines. It had the greatest effect on the mutant, 
VH-PS, but no positive effect at all on VH-Pl, which 
only differed from VH-PS at a single position: residue 47 
was an isoleucine in VH-PS but a glycine in VW-Pl. This 
indicated that residue VH-47 was critical for the nature 
of the exposed interface in the VH. This single point 
mutation also caused the movement of several chemical 
shifts in the aromatic region of VH-Pg and VH-PI 
(Fig. 2). 
For heteronuclear NMR experiments the mutant VH- 
P8 analysed in the presence of CHAPS would now be 
preferable to VH-PI because of its better expression. In 
a 57 ms 2D-TOCSY experiment (Fig. 3) recorded with 
an Hz0 sample of VH-P8. magnetisation transfer from 
the amide to the side chain protons seemed sufficient for 
an assignment after labeling with “N. 
However, for other applications, like the design of 
non-sticky, minimum size immunoreagents, the VW-PI 
mutant might be preferable as a starting point. Its long 
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relaxation time, which was not improved in the presence 
of CHAPS, suggested that there was little aggregation 
through the exposed VHNL interface. In the case of the 
other two VH’s this aggregation was strongly reduced 
through the addition of CHAPS. VH-Pl might, there- 
fore, also be expected to cause less problems through 
non-specific binding in pharmaceutical or biotechnologi- 
cal applications. 
3.4. Stability 
Chemical shift movements in the aromatic region of 
the TOCSY spectra recorded with the wild-type 0x13- 
VH and VH-P8 (Fig. 2) were probably due to the muta- 
tion of residue VH-W47. However, numerous similari- 
ties to the aromatic region of the parent scFv (not shown) 
suggested that indeed all three VH’s formed the normal 
immunoglobulin domain structure. This was further sup- 
ported by their ability to bind protein A-Sepharose, 
which most likely depended on their proper tertiary 
structure. Thus protein A-conjugated peroxidase proved 
a very poor reagent for the detection of VH in Western 
blots of SDS gel denatured protein. 
Other indicators for a correct tertiary structure were 
about 30 D,O stable amide protons observed for both 
the 0x13-VH and the VH-P8 mutant. Most of these 
exhibited TOCSY cross-peaks to downfield-shifted 
C”H’s (compare Fig. 3) indicative of a P-sheet arrange- 
ment [20], which was typical for an immunoglobulin do- 
main and was observed for various Fv’s analysed in our 
laboratory. No appreciable exchange was observed for 
these amides within several weeks. 
In contrast amide protons of the VH-PI mutant were 
almost completely exchanged already several hours after 
preparation of the D,O sample. VH-Pl. however, exhib- 
ited the same downfield-shifted, /?-sheet ypical C”H sig- 
nals seen for the other two VH’s. VH-Pl also formed a 
strong precipitate during the NMR experiments at 313 
K. These preliminary observations hint at different sta- 
bilities of the VH’s but require more detailed investiga- 
tions. Results in this direction might become important 
for the design of stable VH domains as immunoreagents. 
Expression yields of VH’s, equally important for bio- 
technological applications, could also be related to their 
stabilities. 
4. Discussion 
The engineering of VH domains as undertaken in this 
study should prove valuable in different aspects. The 
now possible NMR studies on an isotopically labeled 
VH-P8 domain should specifically ease the NMR analy- 
sis of the parent, scFv. More generally the achieved line 
width reduction showed how a protein, at first unsuitable 
for NMR analysis, can be studied when modified by 
protein engineering in structural regions likely to cause 
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Fig. 3. Amide region of a TOCSY ZD-spectrum recorded in H,O with 
VH-P8 in the presence of 10 mM CHAPS. 
aggregation. This approach could be combined with an 
optimisation of sample conditions through the addition 
of detergent. 
Similar actions might aid the NMR analysis of other 
proteins, where aggregation causes sensitivity problems 
through short relaxation times [17]. Proteins analysed by 
NMR spectroscopy are often expressed and analysed as 
fragments of originally much bigger macromolecules. 
Consequently surfaces or interfaces will be exposed to 
the solvent, which are hidden in the native protein. 
Added detergent or introduced mutations might there- 
fore often render the studied macromolecule no less nat- 
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ural than before, although care will have to be taken with 
respect to effects on the overall structure. 
Regarding the development of small immunoreagents, 
the use of VH’s as minimum recognition units has been 
hampered by problems related to those observed during 
the NMR analysis. The exposed VHNL interface can 
cause non-specific binding to hydrophobic ligands or 
surfaces. Irreversible denaturation at higher concentra- 
tions, as observed for the VH-PI mutant, will be critical 
for scale up procedures in biotechnological applications. 
Similarly a synthetic, VH-like protein containing a 
metal-binding site proved insoluble at higher concentra- 
tions [21]. 
Changes in the VHNL interface like the ones de- 
scribed here might solve these problems. For the design 
of small immunoreagents a library of VH’s based on, for 
example, the non-aggregating VH-PI mutant with ran- 
domised hypervariable loops (CDRs) can be expressed 
on the surface of phage and selected through binding to 
different immobilised antigens. Phage surface-expressed 
scFv libraries with randomised CDRs have already been 
successfully selected for different specificities [121 and 
improved affinity [22]. NMR analysis of resulting VH’s 
would later be greatly simplified through comparisons 
with the VH-P8 domain, which has identical FR se- 
quences, with the exception of residue VH-47. 
Regarding the stability and expression yield of isolated 
VH’s, both seemed to be highly sensitive to the mutations 
introduced in FR2. It will therefore be worthwhile analy- 
sing other mutants in our VH library (randomised at 
position 47) with respect to these parameters. 
It should also be pointed out that the VH mutants 
were designed to match the sequences of camel VH’s 
found in antigen binding immunoglobulins without light 
chains. The mutations analysed here might have enabled 
or even caused antibodies in camels to be expressed as 
immunoglobulins devoid of light chains, thus the FR2 
mutations might prevent proper VHNL interactions. 
This can be tested in association experiments of bacteri- 
ally expressed heterodimeric Fv. 
Antibodies devoid of light chains may also exist in 
species other than camel. Thus the Kabat database of 
immunoglobulin sequences [23] lists one frog VH family 
(VIII, Xenopus lads), which exhibits mutations at posi- 
tions VH-45 and VH-47 similar to those introduced in 
the human VH in our experiments. However, it has not 
been determined whether expressed members of this frog 
VH family form light chain-containing antibodies [24]. 
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